HCP Kit for Automated Impurity Analysis of Biotherapeutics

June 28, 2019
Pharmaceutical Technology Editors

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology\'s In the Lab eNewsletter-07-02-2019, Volume 14, Issue 7

The Gyrolab E. coli HCP Kit quantifies host cell protein impurities from Escherichia coli expression systems used in biotherapeutic production.

Gyros Protein Technologies, a provider of peptide synthesizers and reagents, added a new host cell protein (HCP) kit for the automated impurity analysis of biotherapeutics expressed in Escherichia coli (E. coli) systems to its product offerings. 

The Gyrolab E. coli HCP Kit quantifies HCP impurities from E. coliexpression systems used in the production of biotherapeutics, a critical step in ensuring the efficacy and safety of the drug molecule. According to the company, the new kit is a key tool for the automated analysis of bioprocess samples, offering further support to users working in biotherapeutics process development and manufacturing.

The new kit is optimized for use in Gyrolab systems and has been developed as part of a licensing and supply agreement with HCP and DNA impurity detection solutions provider Cygnus Technologies, incorporating Cygnus’ industry standard E. coli HCP antibodies and other reagents.

Summary: Gyros Protein Technologies